Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

NCT ID NCT03938987
Title Anti-CD19, Dual Co-stimulatory (4-1BB, CD3zeta) Chimeric Antigen Receptor T-cells in Patients With Relapsed/Refractory Aggressive Lymphoma or Acute Lymphoblastic Leukemia (ALL) (ACIT001/EXC002)
Recruitment Recruiting
Gender both
Phase Phase Ib/II
Variant Requirements No
Sponsors University of Alberta

non-Hodgkin lymphoma

acute lymphoblastic leukemia


Cyclophosphamide + Fludarabine

Anti-CD19 CAR T cells

Age Groups: adult | child | senior
Covered Countries CAN

No variant requirements are available.